Physician

Kevin Roe, DO

According to 2025 Medicare claims, Kevin Roe, DO (NPI: 1538309174) practices nephrology in the State College, PA market, with the plurality of this provider's patient population coming from Centre, PA. This provider's primary affiliated billing organization is MOUNT NITTANY MEDICAL CENTER HEALTH SERVICES INC (NPI: 1598992554; TIN: 510426500) and primary practice location at 16652-2409.

Roe's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 237 traditional Medicare patients, billed 2,191 HCPCS/CPT codes, and received $99,675 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 1,695 prescription claims across 294 beneficiaries totaling $689,456 in drug costs, led by Fabrazyme (Agalsidase Beta). DME data shows 35 claims. Open Payments data shows 6 records totaling $119. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $16,913 to $99,675. Similarly, Part D prescription costs have moved sharply higher in recent years, from $80,768 to $689,456. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	71	208	$16,913
2016	162	1,269	$54,616
2017	203	2,879	$65,836
2018	249	848	$86,803
2019	251	987	$101,042
2020	242	1,113	$93,736
2021	249	3,518	$117,049
2022	244	1,632	$110,039
2023	257	1,393	$104,977
2024	237	2,191	$99,675

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	65	214	$80,768
2016	76	379	$9,866
2017	125	865	$43,084
2018	204	1,291	$57,701
2019	199	1,303	$124,088
2020	198	1,401	$165,364
2021	244	1,450	$213,278
2022	262	1,617	$184,654
2023	286	1,620	$369,758
2024	294	1,695	$689,456

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	11	$348
2022	N/R	86	$2,171
2023	N/R	68	$1,255
2024	N/R	35	$361

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	16	126	$266
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	22	22	$117
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	18	20	$99
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	34	157	$88
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	172	321	$80

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Fabrazyme	Agalsidase Beta	26	728	$470,228
Jardiance	Empagliflozin	75	3,828	$73,250
Farxiga	Dapagliflozin Propanediol	14	1,050	$18,921
Eliquis	Apixaban	17	930	$16,944
Entresto	Sacubitril/Valsartan	16	763	$12,267

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	19	$201
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	16	$160

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	6	$119	Boehringer Ingelheim Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Kevin Roe, DO?

Tedicare shows public-source Medicare data for Kevin Roe, DO (NPI 1538309174), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Kevin Roe, DO have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Kevin Roe, DO?

Kevin Roe, DO is linked to MOUNT NITTANY MEDICAL CENTER HEALTH SERVICES INC (billing NPI 1598992554) in the available physician profile data.

Does Kevin Roe, DO have Open Payments data?

Kevin Roe, DO has 6 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.